NEW YORK (GenomeWeb News) - Asuragen said today it has granted global rights to Agendia for use of its RNARetain tissue preservation solution for human diagnostic applications.
 
Under the non-exclusive agreement, Agendia will use RNARetain to store and ship tumor samples for its MammaPrint diagnostic, which predicts the risk of the recurrence of breast cancer.
 
RNARetain, also known as RNAlater, is used to preserve nucleic acid profiles in solid tissues.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.

NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.

The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.

In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.